Roche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a sign...
ZURICH - Roche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a significant number of patients with triple-negative breast cancer, a development hailed by doctors as a promising advance in fighting the aggressive disease.
Roche’s Tecentriq has fallen well behind immunotherapies Keytruda from Merck and Opdivo from Bristol-Myers Squibb in treatment areas such as lung cancer. It hopes beating the two rival therapies in less common diseases like triple-negative breast cancer will help its medicine’s revenue accelerate. More than 250,000 cases of invasive breast cancer are diagnosed annually in the United States, some 15 percent of which are triple-negative.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Roche's Tecentriq wins U.S. approval for aggressive breast cancerRoche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a sign...
Read more »
Kevin Roche Imagined Work Spaces to Make Office Life LivelierIrish-born architect Kevin Roche, who died March 1 at age 96, was celebrated as a designer of quirky corporate headquarters that featured indoor gardens concealed parking spaces and rooftop green spaces.
Read more »
Pritzker Prize, Irish-born architect Kevin Roche diesAcclaimed Irish-born architect Kevin Roche dies, leaving his mark on world-class buildings from New York's Metropolitan Museum of Art and the city's Museum of Jewish Heritage to airports in New York and Washington.
Read more »
Kevin Roche, leading corporate architect of postwar boom years, dies at 96He also became an architect of choice for the Metropolitan Museum of Art and other major institutions.
Read more »
We just got an inside look at the dramatic 10 weeks that sealed a cutting-edge, $4.8 billion biotech acquisitionThe biotech Spark played its suitor, Roche, off against another interested buyer to boost the size of the proposed deal by more than 60%.
Read more »
Roche's Tecentriq wins U.S. approval for aggressive breast cancerRoche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a sign...
Read more »
US Aid Cuts Are Making It Harder For Palestinian Women To Treat Their Breast CancerMore than 1,000 women who had mammograms done through a US-funded program and were flagged for follow-ups have had to seek other treatment options.
Read more »
FDA approves first immunotherapy regimen for breast cancerThe US Food and Drug Administration granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday. The drug, Genentech's Tecentriq, was approved for use in combination with Abraxane chemotherapy for patients who have a type of advanced triple negative breast cancer.
Read more »
J&J nasal spray gets U.S. approval as first new type of anti-depressant in decadesThe U.S. Food and Drug Administration on Tuesday said it approved a Johnson & Jo...
Read more »